BofA analyst Allen Lutz lowered the firm’s price target on GoodRx (GDRX) to $2.60 from $3 and keeps an Underperform rating on the shares. Heading into 2026, the firm maintains its positive view on the drug distributor group and updates its price targets to reflect peer group multiple changes.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GDRX: